BOWAVE Pharmaceuticals, Bin Tie Bio, and Biocells Secure Over $100M in Recent Funding Rounds; All Three Companies File IPO Prospectuses

1、New Force in siRNA - Argo Completes 300 Million Yuan A+ Round Financing

News on November 1: Argo Biopharma has recently completed a RMB 300 million Series A+ round of financing. This round was led by SDIC Venture Capital, with participation from Huagai Capital, Yuanxi Haihe Fund, and existing investor Sanyi Innovation Investment. The proceeds will be used to further advance the global development of four clinical pipelines, discover multiple preclinical candidate drug molecules (PCC), upgrade modification technology platforms and extrahepatic delivery technology platforms, as well as enhance the company's professional team building.

Argo, established in April 2021, focuses on the development of siRNA drugs and was founded by several scientists with extensive experience in siRNA drug development. The company is committed to developing a new generation of siRNA drugs to provide urgently needed and better treatment options for patients worldwide. It is reported that the Argo team has many years of professional experience in all aspects of RNAi drug development, including nucleic acid sequence design, chemical modification, GalNAc delivery technology, extrahepatic tissue-targeted delivery technology, oligonucleotide synthesis, and CMC, and has already built a complete nucleic acid drug development platform at Argo.

2. Series A Breaks 100 Million, ImmuXell Biotech Advances TCR-T Therapy

Recently, ImmuXell Biotech LtD. (referred to as "ImmuXell Biotech") announced the completion of an over 100-million-yuan Series A financing round. This round was led by SDIC Venture Capital, with participation from Huangpu Pharmaceutical Fund, Yuanxi Haihe Fund, and others, supporting ImmuXell Biotech in advancing new technology R&D, commercial production implementation, and international business strategy layout. The funds raised will be used to accelerate the application for registration clinical trials of a novel TCR-T cell therapy product targeting KRASG12V mutations, as well as the product development and international cooperation of multiple subsequent innovative pipelines.

ImmuXell Biotech is a clinical-stage biopharmaceutical innovation company focused on the research and production of breakthrough immunotherapy drugs. Its main product is a novel immune cell preparation targeting solid tumors—TCR-T products aimed at KRAS mutations for treating recurrent and refractory malignant tumors such as pancreatic cancer. It has completed TCR screening, in vitro functional validation, and in vivo efficacy experiments, and has conducted investigator-initiated trials (IIT) for advanced pancreatic ductal adenocarcinoma across multiple clinical centers domestically and internationally. It is currently in the preparation stage for IND submission.